Type 1 diabetes
By Mark Atkinson, G. Eisenbarth, A. Michels. The Lancet, 2013
1,310 citations recorded by the source corpus.
Over the past decade, knowledge of the pathogenesis and natural history of type 1 diabetes has grown substantially, particularly with regard to disease prediction and heterogeneity, pancreatic pathology, and epidemiology. Technological improvements in insulin pumps and continuous glucose monitors help patients with type 1 diabetes manage the challenge of lifelong insulin administration. Agents that show promise for averting debilitating disease-associated complications have also been identified. However, despite broad organisational, intellectual, and fiscal investments, no means for preventing or curing type 1 diabetes exists, and, globally, the quality of diabetes management remains uneven. This Seminar discusses current progress in epidemiology, pathology, diagnosis, and treatment of type 1 diabetes, and prospects for an improved future for individuals with this disease.
Subfields: Endocrinology, Diabetes and Metabolism, Genetics, Surgery
View Paper: https://www.semanticscholar.org/paper/ccf6368e512dc0a0144b3ad5ad866bef8cfeee40
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- E. Oikonomou
- G. Vogiatzi
- G. Papamikroulis
- D. Tousoulis
- S. Tsalamandris
- A. Antonopoulos
- S. Deftereos
- S. Papaioannou
Citations in the corpus
- The Role of Inflammation in Diabetes: Current Concepts and Future Perspectives (2018, background): “destruction of insulin-producing pancreatic beta cells, without apparent pathological alterations of other Langerhans cells.(25) However, T1D shows significant heterogeneity in regard to the age of onset, severity of autoimmune response and efficacy of therapy, while it has also been demonstrated th”